Abpro Corporation

Contributing Author

Recent Articles by Abpro Corporation

Jan-15	Abpro's Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference ABP -8.60% GlobeNewswire
Jan-06	Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72 ABP +19.75% GlobeNewswire
Dec-15	Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers ABP GlobeNewswire
Dec-09	Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives ABP +6.26% GlobeNewswire
Nov-04	Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2xCD3 T-Cell Engager ABP GlobeNewswire
Nov-03	Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025 ABP GlobeNewswire